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The protein kinase B-Raf proto-oncogene, serine/threonine kinase (BRAF) is an oncogenic driver and therapeutic target in melanoma. Inhibitors of BRAF (BRAFi) have shown high response rates and extended survival in patients with melanoma who bear tumors that express mutations encoding BRAF proteins mutant at Val600, but a vast majority of these patients develop drug resistance 1, 2 . Here we show that loss of stromal antigen 2 (STAG2) or STAG3, which encode subunits of the cohesin complex, in melanoma cells results in resistance to BRAFi. We identified loss-of-function mutations in STAG2, as well as decreased expression of STAG2 or STAG3 proteins in several tumor samples from patients with acquired resistance to BRAFi and in BRAFi-resistant melanoma cell lines. Knockdown of STAG2 or STAG3 expression decreased sensitivity of BRAF Val600Glu -mutant melanoma cells and xenograft tumors to BRAFi. Loss of STAG2 inhibited CCCTCbinding-factor-mediated expression of dual specificity phosphatase 6 (DUSP6), leading to reactivation of mitogenactivated protein kinase (MAPK) signaling (via the MAPKs ERK1 and ERK2; hereafter referred to as ERK). Our studies unveil a previously unknown genetic mechanism of BRAFi resistance and provide new insights into the tumor suppressor function of STAG2 and STAG3.
Several genetic mechanisms mediating resistance to BRAFi have been described, including mutations in genes encoding components of the MAPK pathway (NRAS, MAP2K1, MAP2K2 and NF1) and the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)-protein kinase B (PKB, also known as AKT) pathway (PIK3CA, PIK3R1, PTEN and AKT) [3] [4] [5] [6] [7] [8] . However, a portion (18-26%) of BRAFi-resistant melanomas are not driven by any of these known resistance mechanisms 4, 5, 9 .
To identify additional mechanisms of acquired resistance to BRAF inhibition, we performed whole-exome sequencing on a pair of pretreatment and post-relapse melanoma tumor samples from a patient who was treated with the BRAFi vemurafenib and who had a time-to-disease-progression of 5 months. We compared the list of mutations identified exclusively in the post-relapse sample from this patient with a set of 127 significantly mutated genes (SMGs) that were previously identified from The Cancer Genome Atlas (TCGA) pancancer analysis 10 and found that there was only one SMG (STAG2) that was mutated in the post-relapse sample (Supplementary Table 1 ). This mutation in STAG2 (c.577G>A, resulting in Asp193Asn) was subsequently confirmed by Sanger sequencing. Although the pretreatment sample contains trace amounts of the mutated allele, it is greatly enriched in the post-relapse sample (Fig. 1a) . STAG2 (also known as SA2) encodes a core subunit in the cohesin complex, which regulates cohesion and segregation of sister chromatids 11, 12 .
Mutations in STAG3 and in other genes that encode cohesin complex subunits (such as SMC1A, SMC3 and RAD21) have been shown to occur frequently in various cancers-such as urothelial bladder carcinomas, Ewing sarcoma, acute myeloid leukemia, myelodysplastic syndrome and acute megakaryoblastic leukemia [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . We found that the STAG2 Asp193Asn mutation decreases the binding affinity of the STAG2 to RAD21 and SMC1A, suggesting that c.577G>A is a loss-of-function mutation (Supplementary Fig. 1a ). STAG2 has two other paralogs in mammals, STAG1 and STAG3. Data from the melanoma TCGA project 24 indicated that mutation frequencies of the genes encoding these three proteins are ~4% (STAG2), 3% (STAG1) and 5% (STAG3), for a total nonredundant mutation rate of ~10%. We therefore examined expression of all three STAG proteins in a panel of melanoma cell lines that have acquired BRAFi resistance after chronic exposure to BRAFi 25, 26 and found that both STAG2 and STAG3, but not STAG1, protein levels were reduced in several BRAFi-resistant (BR) cell lines and in BRAFi and MEKi double-resistant (BMR) lines, as compared to their drug-sensitive counterparts (Fig. 1b) . We subsequently performed Sanger sequencing of all of the coding exons of STAG2 and STAG3 in these cell line pairs and identified a STAG2 nonsense mutation (c.3247A>T, resulting in a change of Lys1083 to a stop codon (Lys1083*)) in WM902-BR cells that was not present in the parental WM902 cells (Supplementary Fig. 1c ).
Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma
No mutations in STAG3 were identified in our cell line panel. However, when we analyzed data from a published whole-exome sequencing study of 45 patients with BRAF Val600 -mutant metastatic melanoma who received vemurafenib or dabrafenib monotherapy 4 , we found three STAG3 mutations in pretreatment samples from 14 patients who developed early resistance to therapy (<12 weeks; Supplementary Table 2) . We detected STAG3 mutations in post-relapse, but not pretreatment, samples from an additional six patients from this study (Supplementary Table 2 ). Although the significance of STAG3 mutations was not reported in the original study 4 , we found that two of these mutations reduced the binding affinity of STAG3 to RAD21 (Supplementary Fig. 1d ). Finally, we compared the expression of the STAG2 and STAG3 proteins, using immunohistochemical analysis, in pairs of pretreatment and post-relapse tumor samples from patients who had been treated with BRAFi monotherapy or with BRAFi and MEKi combination therapy. Four and three post-relapse samples, respectively, of a total of nine pairs of samples, showed decreased levels of STAG2 and STAG3 proteins, relative to their paired pretreatment samples ( Fig. 1c and Supplementary Fig. 1e) . Two of these samples showed reductions in both STAG2 and STAG3 expression. We did not detect mutations in coding exons in the STAG2 or STAG3 genes in these post-relapse samples, suggesting that their downregulation was mediated through epigenetic mechanisms. Taken together, these results suggest that mutations in STAG2 and STAG3 that decrease expression of their proteins are involved in clinical development of BRAFi resistance in patients with melanoma.
To examine whether loss of STAG2 or STAG3 is sufficient to confer resistance to BRAF inhibition, we used at least two independent shRNAs to knock down the expression of either STAG2 or STAG3 in various BRAF-mutant melanoma cell lines and examined whether this altered their sensitivities to pharmacological inhibition of BRAF. In cell viability assays using the tetrazolium dye MTS, A375 cells expressing the STAG2-specific shRNA showed lower sensitivity to the BRAFi dabrafenib, as compared to cells expressing a scrambled control shRNA (Fig. 2a) . Knockdown of STAG2 expression also resulted in increases in the basal levels of phosphorylated (p)-ERK and in a reduction in the ability of dabrafenib to inhibit ERK phosphorylation in these cells (Fig. 2b) . However, levels of phosphorylated AKT (p-AKT) and ribosomal protein S6 (p-S6) were not affected by knockdown of STAG2 (Fig. 2b) . Similarly, inducible expression of an independent shRNA targeting STAG2 expression also decreased the sensitivity of SKMEL28, A375 and M14 cells to either dabrafenib or vemurafenib (Fig. 2c,d and Supplementary Fig. 2a−h) . Knockdown of STAG2 also decreased sensitivity of A375 cells to the MEKi trametinib either alone or in combination with dabrafenib ( Supplementary Fig. 2i-l) . In addition to BRAF-mutant melanoma cells, we found that in NRAS-mutant SKMEL30, SKMEL103 and 501MEL melanoma cells, depletion of STAG2 by shRNA treatment also induced resistance to trametinib, as indicated by its inability to inhibit ERK phosphorylation and reduce cell viability in these cells (Fig. 2e,f and Supplementary  Fig. 3a−e) . Similar to STAG2, knockdown of STAG3 in BRAF-mutant melanoma cells also resulted in decreased sensitivity to dabrafenib or vemurafenib with regard to cell viability and ERK inhibition (Fig. 2g,h and Supplementary Fig. 4a−d) . Co-depletion of both STAG2 and STAG3 further reduced the ability of vermurafenib to inhibit p-ERK signaling in A375 cells, as compared to that observed with knockdown of STAG2 or STAG3 alone (Supplementary Fig. 4e ). Furthermore, we found that either STAG2 or STAG3 knockdown in A375 cells markedly impaired the changes in cell cycle progression and reduced the percentages of annexin V + apoptotic cells in response to vemurafenib treatment (Supplementary Fig. 5 ). These data suggest that loss of STAG2 or STAG3 decreases sensitivity to BRAF pathway inhibition through reactivation of ERK signaling.
Next we examined the effects of the ectopic expression of STAG2 and STAG3 on BRAFi sensitivity in BRAF-mutant melanoma cells. Expression of Flag-tagged wild-type STAG2 and STAG3, but not STAG2 Lys1083* or STAG2 Asp193Asn , in WM902-BR cells increased the ability of vemurafenib to inhibit ERK activity and to reduce colony formation in soft-agar Fig. 6c-g ). These results further support the idea that STAG2 and STAG3 regulate the sensitivity of melanoma cells to BRAFi. We then sought to determine whether STAG2 and STAG3 regulate responses to BRAF inhibition in melanoma in vivo. A375 cells that inducibly expressed the STAG2-specific shRNA were grown as xenograft tumors in nude mice to assess their sensitivity to vemurafenib. Silencing of STAG2 expression did not significantly affect A375 xenograft tumor growth in nude mice (Fig. 3a) . However, tumors with STAG2 knockdown showed significantly decreased sensitivity to vemurafenib-induced tumor shrinkage as compared to that in control mice (Fig. 3a,b) . Immunohistochemical analysis revealed that p-ERK levels in STAG2-knockdown tumors treated with vemurafenib were higher than those in the tumors of the control group (Fig. 3c) . Similar effects to the responses of the A375 xenograft tumors to vemurafenib were observed for knockdown of STAG3 (Fig. 3d-f ). Together these data support the notion that loss of STAG2 or STAG3 decreases the sensitivity of melanoma tumors to BRAF inhibition in vivo.
We next investigated the molecular mechanism underlying the regulation of protein kinase signaling cascade RAF-MEK-ERK by STAG2. We first examined the effect of STAG2 knockdown on RAS GTPase activation in melanoma cells. Knockdown of STAG2 did not affect the levels of GTP-bound RAS in A375 or SKMEL28 cells, as demonstrated in RAF1 RAS-binding domain (RBD) pull-down assays, using glutathione-S-transferase (GST)-tagged RAF1 RBD ( Supplementary  Fig. 7a ). Because silencing of STAG2 caused significant increases in the basal levels of p-ERK (Fig. 2) , we next assessed whether STAG2 regulates ERK activities through ERK phosphatases, such as DUSP4 and DUSP6, which are key players in the BRAF-MEK-ERK pathway 6 . shRNA-mediated knockdown of STAG2 or STAG3 expression led to significant decreases of DUSP6 but not DUSP4 mRNA levels in A375 and M14 melanoma cells ( Fig. 4a and Supplementary Fig. 8a,b) . Similar effects for DUSP6 protein levels were observed in melanoma cells with STAG2 or STAG3 knockdown (Fig. 4b,c and Supplementary  Fig. 8c ). In addition, we assessed the effect of ectopic STAG2 expression on DUSP6 protein abundance. Expression of wild-type STAG2, but not STAG2 Lys1083* or STAG2 Asp193Asn , increased DUSP6 protein expression in HEK293 cells (Fig. 4d) . DUSP6 protein expression was also reduced in BRAFi-resistant melanoma cell lines, as compared to their parental BRAFi-sensitive counterparts (Supplementary Fig. 8d ). These findings support the concept that STAG2 controls the expression of DUSP6 in melanoma cells. The cohesin complex, of which STAG2 is a major component, can interact with CCCTCbinding factor (CTCF) and participate in DNA-looping interactions between promoters and distal regulatory DNA elements, thereby controlling gene expression 12, 27, 28 . The promoter region of DUSP6 contains a CTCF-binding site (Fig. 4e) , as identified in previous whole-genome chromatin immunoprecipitation followed by sequencing (ChIP-seq) analyses of CTCF-binding sites 29 . We performed ChIP analyses in A375 and M14 melanoma cells with a CTCF-specific antibody and confirmed that CTCF binds to the DUSP6 locus in these cells (Fig. 4f  and Supplementary Fig. 9a ). shRNA-mediated knockdown of STAG2 expression significantly reduced the binding of CTCF to the DUSP6 locus, but not to the well-established CTCF-binding site in the H19 locus ( Fig. 4f and Supplementary Fig. 9a) . Expression of STAG2 Lys1083* or STAG2 Asp193Asn abolished the binding of CTCF to the DUSP6 locus in LOX-IVMI cells, as compared to cells expressing Flag-tagged wild-type STAG2 (Fig. 4g) . Similarly, we found that binding of CTCF to the DUSP6 locus is much stronger in WM902 cells than in WM902-BR cells that carry the STAG2 Lys1083* mutation (Supplementary Fig. 9b) . Finally, to determine whether DUSP6 mediates the effect of STAG2 on the BRAFi response, we overexpressed Myc-tagged DUSP6 and the STAG2-specific shRNA in A375 cells; restoration of DUSP6 expression attenuated the induction of basal p-ERK levels by STAG2 silencing and enhanced the ability of vemurafenib to inhibit ERK activities and to reduce clonogenic growth in cells after STAG2 knockdown (Fig. 4h,i) . Similar effects of ectopic DUSP6 expression were also observed in M14, WM902-BR and WM983-BR melanoma cells (Supplementary Fig. 10a-d) . However, overexpression of DUSP4 did not seem to affect ERK activity in A375 cells that expressed either the STAG2-specific shRNA or the scrambled control shRNA (Supplementary Fig. 10e ). Taken together, our results strongly suggest that loss of STAG2 inhibits CTCF-mediated expression of DUSP6, leading to reactivation of MEK-ERK signaling in BRAFi-treated melanoma cells. Our findings not only reinforce the concept that reactivation of ERK signaling represents a major resistance mechanism of BRAF pathway inhibition 3, 6, 9 , but they also reveal a previously unappreciated connection between STAG proteins and ERK signaling. With the recent advances in the field of cancer genomics, STAG2 and the genes encoding other components of the cohesin complex have emerged as frequent targets of somatic alterations in a wide variety of cancers of different origins 11, 12 . In addition to a canonical function in sister chromatid cohesion and segregation, the cohesin complex has a notable role in chromatin organization and transcription 11, 12 . Whereas SMC1, SMC3 and RAD21 form the cohesin ring structure that entraps sister chromatids, STAG2 interacts with RAD21 at the base of the ring and has a regulatory rather than a structural role in the cohesin complex. How STAG2 exerts its tumor suppressor functions remains an open question. Sister chromatid cohesion, instead of regulation of the global transcription program, was proposed as the major tumor suppressor function of STAG2 (ref. 13 ). Inactivation of STAG2 causes cohesion defects and aneuploidy in glioblastoma and colorectal carcinoma cell lines 13 . However, cytogenetic abnormalities do not appear to be associated with STAG2 mutations in leukemia, bladder cancer and Ewing sarcoma according to several recent cancer genomics studies 14, 18, 19 , suggesting that aneuploidy may not underlie the tumor suppression role of STAG2 in these cancers. Notably, CTCF-and cohesin-binding sites have been recently reported to be frequently mutated in various types of cancers 30 . Our discovery of the regulation of the ERK signaling pathway by STAG2 or STAG3 not only supports a critical role of STAG2 in regulating DUSP6 gene expression through CTCF (Supplementary Fig. 11 ), but it also reveals a new dimension of their tumor suppressive capacity.
METHODS
Methods and any associated references are available in the online version of the paper. The investigators were blinded to group allocation and outcome assessment. Tumor biopsies were sectioned at 4 µm and stained manually with primary antibodies for STAG2 (1:100, Santa Cruz, SC-81852) and STAG3 (1:200, Abcam Ab185109), followed by a secondary horseradish-peroxidase-conjugated antibody (DAKO K4003 for STAG3 or DAKO K4001 for STAG2) and Bajoran Purple chromogen kit (Biocare Medical BJP811). All slides were counterstained with hematoxylin (Vector H-3401). Stained slides were interpreted by a dedicated dermatopathologist.
Sequencing. Genomic DNA samples extracted from pretreatment and post-relapse fresh-frozen paraffin-embedded (FFPE) tissues of a patient who relapsed from vemurafenib treatment were subjected for whole-exome sequencing analysis using the Agilent SureSelect Human All Exon 51M kit at BGI (Beijing, China). Reads were mapped to hg19 using bwa 31 . PCR duplicates and non-uniquely mapped reads were discarded using SAMtools 32 . Varscan2 (ref. 33 ) was further used to call somatic mutations, and the results were annotated by ANNOVAR 34 . Mutations that mapped to segmental duplications or were annotated in 1000 Genome Project and dbsnp138 were filtered afterwards. Only nonsynonymous, stop-gain, stop-loss mutations were selected for later analysis. High-confident mutations were further picked based on the total coverage, coverage for reference allele, coverage for altered allele and functional prediction from Polyphen2 (ref. 35) . For high-throughput Sanger sequencing, all coding exons and intron-exon junctions in the STAG2 and STAG3 genes were amplified by PCR, followed by DNA sequencing and singlenucleotide polymorphism (SNP) discovery data analysis at Polymorphic DNA Technologies (Alameda, CA). To confirm the STAG2 mutations found in patient samples and cell lines, PCR reactions were performed for exon 7 and exon 29 with the following pairs of primers: 7F, 5′-GATAGTGGAGATTATCCACTT AC-3′, 7R, 5′-CTGCCAGGGTGCTTGTATGTCG-3′; 29F, 5′-ATGCCTATG CTCGCACAACT-3′, 29R, 5′-ATACTGAGTCCATTTCCCTATGC-3′. NRAS Gly12Asp mutation in 501MEL cells 36 was confirmed by PCR amplification of exon 2 with primers: 2F, GAACCAAATGGAAGGTCACA and 2R, TGGGTAAAGATGATCCGACA, followed by Sanger sequencing.
Materials.
Information on the antibodies used in this study are listed in Supplementary Table 3 . Validations of all antibodies are provided on the manufacturer's websites. Vemurafenib, dabrafenib and trametinib were purchased from Selleck Chemicals. Doxycycline, crystal violet and iodonitrotetrazolium chloride were purchased from Sigma. pLEX-HA-DUSP6-MYC was provided by Dr. Igor Astsaturov and pLJM1-STAG2 by Dr. Todd Waldman through Addgene. pLX304-DUSP4-V5 was purchased from the DNASU Plasmid Repository. The Flag-tag-encoding sequence was added to the N-terminusencoding sequence of DUSP4 to generate pLX304-FLAG-DUSP4-V5, using PCR-based methods. pBabe-FLAG-STAG2 was generated by PCR-based subcloning from pLJM1-STAG2. pBabe-MYC-BRAF was generated by PCR-based subcloning from pLHCX-FLAG-BRAF 37 . pBabe-FLAG-STAG3 was generated by PCR-based subcloning using STAG3 cDNA purchased from GE Dharmacon as a template. Various mutated STAG2, STAG3 and BRAF alleles were generated using PCR mutagenesis and verified by sequencing. pLKO constructs containing shRNAs against human STAG2 (shSTAG2#23:TRCN0000152523) and STAG3 (shSTAG3#96: TRCN0000137596; shSTAG3#71: TRCN0000138271; shSTAG3#69: TRCN0000138869) were purchased from Sigma. pTRIPZ inducible lentiviral human STAG2 shRNA (shSTAG2#60 CloneID:V2THS_12573) and STAG3 shRNA (shSTAG3#55 CloneID:V3THS 301555) were purchased from GE Dharmacon.
Cell culture. All melanoma cell lines used in this study contain BRAF Val600Glu mutations, except as otherwise indicated. A375 and SKMEL28 cells were purchased from the American Type Culture Collection (ATCC). LOX-IVMI cells were obtained from the Division of Cancer Treatment and Diagnosis, National Cancer Institute, (NCI-DCTD) repository. WM902, WM902-BR, WM983, WM983-BR and MEL1617 cell lines were obtained from Dr. Meenhard Herlyn (Wistar Institute). Immortalized Braf-null mouse embryonic fibroblasts (MEFs) were a gift from Dr. Catrin Pritchard (University of Leicester) 38 . 501MEL and SKMEL103 cells, harboring NRAS mutations, were gifts from Dr. Lynda Chin (MD Anderson Cancer Center) and Dr. Jonathon Zippin (Weill Cornell Medical College), respectively. These cell lines were not authenticated by us. WM902, WM983, M14, MEL1617, SKMEL28, A375, LOX-IVMI, 501MEL and SKMEL103 cells were cultured in RPMI containing 10% FBS (FBS) and penicillin-streptomycin-glutamine (PSG). HEK293 and MEF cells were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% FBS and PSG. WM902-BR, WM983-BR, M14-BR, A375-BR and Mel1617-BR cells were maintained in complete medium supplemented with vemurafenib or dabrafenib. A375-BMR and MEL1617-BMR cells were maintained in complete medium supplemented with dabrafenib and trametinib. For the cell-viability analysis, cells were seeded in 96-well plates, and drug treatment was started the following day. After a 72-h incubation, the MTS assay was performed according to the manufacturer's instructions (Promega). All cell lines tested negative for mycoplasma, using the MycoSensor PCR Assay Kit (Agilent Technologies). Transfection, retroviral infection and lentiviral infection were performed as previously described 25 . When indicated, stable populations were obtained and maintained by selection with puromycin (Sigma). Clonogenic growth 25 and anchorage-independent growth soft-agar assays 39 were performed as previously described.
Cell cycle and apoptosis analyses. For cell cycle analysis, cells were fixed drop wise with 70% ice-cold ethanol for 30 min on ice and suspended in PBS containing 10 µg/ml of propidium iodide (PI) and 10 µg/ml of RNase A. PI-stained samples were analyzed for cell cycle progression by flow cytometry, using a FACScalibur (Becton and Dickinson) apparatus, followed by data analysis using the FlowJo software (TreeStar). For apoptosis analysis, apoptotic cells were detected using BD FITC Annexin V Apoptosis Detection Kit followed by flow cytometry analysis.
Western blotting and immunoprecipitation. Western blotting and immunoprecipitation were performed as previously described 39 . RAS activity assay was performed using active RAS pulldown and detection kit, according to manufacturer's instructions (Thermo Scientific). Briefly, 500 µg of cell lysates were incubated with GST-RAF1-RBD and glutathione resin at 4 °C for 1 h. After washing, the active RAS was eluted by 2× reducing sample buffer and subjected for SDS-PAGE and immunoblotting.
Mouse studies. All studies and procedures involving mice were performed following Massachusetts General Hospital Institutional Animal Care and Use Committee (IACUC) guidelines. For xenograft models, 6-week-old female athymic mice (NCr nu/nu ) were purchased from Taconic farms. Animals were allowed a 1-week adaptation period after arrival. A375 cells (1 × 10 6 in 0.2 ml of basal culture medium) were injected subcutaneously in the right lateral flank. To induce silencing of STAG2 in vivo, 2 mg/ml doxycycline and 5% sucrose were added to the drinking water 13 d after inoculation. Doxycyclinecontaining water was changed every 3 d. Vemurafenib diet (1.42 g per kg body weight to achieve a 25 mg per kg body weight daily dose) and control diet were prepared at Harlan Laboratories (Madison, WI). Animals were randomly assigned to four groups, which were administered vehicle (5% sucrose in water), doxycycline, vehicle and vemurafenib, or both doxycycline and vemurafenib by the Research Randomizer at http://www.randomizer.org. The investigators were not blinded to group allocation or outcome assessment. 
